BMS walks from PBS price talks

By Megan Brodie 3 years ago | In Companies, Products, Regulatory
  • 3 years ago
BMS says 'no go' to its latest PBAC recommendation (istock.com/Dilok Klaisataporn)

3 November 2021 BMS has pulled its blockbuster immuno-oncology drug OPDIVO (nivolumab) from post-PBAC pricing…

This is subscriber-only content. Please login to continue reading.